Given the redundant functions of the Pim family kinases established in lymphoid malignancies, it is conceivable that MM cells are capable of upregulating Pim-1 or Pim-3 as a survival mechanism if Pim-2 alone is targeted, and pan-Pim inhibition is most likely to be useful in the clinic. This evidence concerns the gene PIM2 and Miyoshi myopathy.